This study is the inMIND study. inMIND is a phase III randomised, double-blinded, placebo-controlled, multicentre study evaluating the addition of tafasitamab to rituximab with lenalidomide in patients with relapsed or refractory indolent follicular or marginal zone lymphoma. The primary endpoint of the study was progression free survival for the follicular lymphoma patient population.

What were the results of this study?

This was a 548-patient study and it demonstrated a significant progression free survival improvement with the addition of tafasitamab to rituximab with lenalidomide. The median progression free survival for the tafasitamab-containing arm was 22.4 months compared to 13.9 months without tafasitamab. There was a 57% reduction in risk of progression, relapse or death observed with the addition of tafasitamab and benefit was observed in all prespecified subgroups, including those who were heavily pretreated, the POD24 patient population, or patients who were refractory to prior anti-CD20 monoclonal antibody therapy. Although overall survival data is currently immature, a trend in favour tafasitamab is observed.

What do you think is the significance of these results?

The study is the first to validate the approach of combining two monoclonal antibodies, anti-CD19 and anti-CD20, for the treatment of follicular lymphoma. The results of the study are very exciting; it will potentially change the treatment landscape for this disease. This is proof of concept for future studies that combining two monoclonal antibody therapies simultaneously is effective and safe.

Is there anything else you would like to add?

The safety profile for inMIND was manageable and consistent with expected toxicities for these agents.